ACS is a consulting firm focused on the future of biopharma.

Led by entrepreneurs with decades of industry experience, we focus on helping clients navigate the changing pharma landscape by using cutting-edge approaches to pharmaceutical strategy.

What We Do

We aim to empower the biopharma industry with the latest strategies.

Our consultants partner with our clients to help them fully realize and communicate the value of their innovative assets to all stakeholders: healthcare providers, patients, and payers. We work primarily in specialty therapeutic categories, with a heavy focus on rare diseases.

Work With Us

Our Process

We deploy an agile approach that allows our clients to achieve meaningful outcomes on an accelerated timeline.

Focused Expertise

Current state assessment informed by deep biopharma industry knowledge and experience

Ideation

Strategic planning with a focus on landscape trends

Innovation

Detailed roadmap-planning with a pragmatic mindset

Data-Driven Results

Accountable KPI measurement and monitoring

Our Team

With decades of biopharma industry knowledge and experience, we provide hands-on senior leadership and project teams optimized for your needs.

Ned Kitfield

Head of Corporate & Commercial Strategy

Ned Kitfield

Head of Corporate & Commercial Strategy

Ned Kitfield leads the Corporate and Commercial Strategy Practice at Ambit Consulting Services.  Ned has 20 years’ experience in commercial roles of increasing responsibility at biopharma companies large and small including Bayer, Sanofi, Adolor, and Shire (now Takeda).  Roughly half of his time in biopharma was focused on launching and running brands for ultra-orphan diseases in the US and around the world.  Ned joined C1 consulting (acquired by CRA in 2017) in 2014 as managing director and head of the rare disease practice and quickly built a track record for leading successful new product launches in the rare disease space.

Aileen Nicoletti

Managing Director

Aileen Nicoletti

Managing Director

Aileen Nicoletti directs our biopharma consulting firm. With 20 years of experience in pre-commercial biotech strategy and launch preparation, she has the strategic and scientific expertise to deliver quality insights and strategies well supported by deep market understanding. She cares deeply about building a culture at ACS that provides the best work for the client and maximizes development of the team.

Ben Zipkin

Head of Digital

Ben Zipkin

Head of Digital

Ben Zipkin leads digital strategy and execution for the company. With 20 years of experience, he has the subject matter expertise to glean actionable insights from digital data, identify market needs, and develop winning strategies. Ben’s team also provides data analytics that give rapid feedback on the success of innovative digital strategies. He adds a unique toolkit that strengthens ACS’s strategic offerings as digital becomes increasingly important to successful development and commercialization.

Kim Tully

Principal Consultant, Medical Affairs Strategic Practice​

Kim Tully

Principal Consultant, Medical Affairs Strategic Practice​

Kim brings 25+ years of experience in drug commercialization, medical affairs strategy, leading innovation, and delivering on launch excellence. Kim’s deep knowledge and expertise spans across a wide range of therapeutic areas with a focus in rare disease, oncology, hematology, dermatology, immunology, and neurology. Kim has held various Senior Leadership positions throughout her career including Senior Vice President at Eversana, Global Commercial Director at Bayer and Merck Oncology, Director/Head of Marketing at Sun Pharma, and held various other roles throughout her career. She has also been a subject matter expert, principal consultant, and key advisor to numerous pharma biotech companies. Kim began her professional career as a Registered Nurse (RN) at Rush Presbyterian St. Lukes hospital in Chicago. She holds a BSN from Rush Presbyterian St. Lukes, an MSN from Thomas Jefferson University, and an MBA degree from the Philadelphia School of Pharmacy. She is also a professional coder and member of  American Association of Professional Coders (AAPC) and Oncology Nursing Society (ONS).Kim currently resides in NJ with her husband and has two children. ​

Scott Dubow

Principal, Digital Strategy

Scott Dubow

Principal, Digital Strategy

Scott Dubow brings 20+ years of experience in all aspects of digital marketing, including lead generation and nurturing programs, content and social marketing, experiential and retail marketing, web and app builds and data analytics. Scott’s experience crosses DTC, B2B and HCP marketing roles for rare disease brands including Elzonris in blastic plasmacytoid dendritic cell neoplasm (BPDCN), Sylvant in Idiopathic multicentric Castleman disease (iMCD), Renvela in hyperphosphatemia, Alemtuzumab in MS as well as leading the marketing team at the telehealth firm, American Well. Scott holds a BA from Penn State and an MBA from Northeastern University. He was born and raised in Southern California, currently he lives in Wakefield, Massachusetts with his wife Janet and their two sons, Jack and Alex.

Emily Hoffman

Manager

Emily Hoffman

Manager

Emily brings an engineering mindset and an emphasis on collaboration to her engagements. She balances organization and creativity to highlight the insights most valuable to clients. Her favorite project synthesize primary research with deep data analysis as both sides are needed to tell a great story. Emily has 5+ years of consulting experience with a focus on understanding and communicating product value. She care deeply about developing the junior team and leads our campus/consulting club recruiting efforts.

Allie Kolberg-Edelbrock​

Senior Consultant

Allie Kolberg-Edelbrock​

Senior Consultant

Allie has more than 8 years of experience in engineering and life sciences. Her drive to tackle seemingly unsolvable problems began during her PhD where she developed and patented novel biomaterials to treat spinal cord injury. She took this passion into her career in consulting where she found her niche in rare diseases where few, if any, treatments exist. ​

During her time as a commercial strategy consultant, she gained therapeutic area acumen in rare diseases across gastroenterology, oncology, neurology, and immunology. She has considerable experience executing primary market research and is energized by facilitating insightful discussions with experts and patients ‘on the ground.’ Having the opportunity to create lasting change for patients with high unmet need ‘gets her out of bed in the morning.’

Arthi Krishna

Consultant

Arthi Krishna

Consultant

Arthi Krishna has a unique background in clinical medicine paired with public health and policy. She has a wide background in the life sciences with concentrations in neuroscience and botany. She is interested in bridging the gap between technology and medicine and focusing on the future of biotech/pharma. She cares deeply about team development and recruiting efforts at ACS.

Jim McKenna

Consultant

Jim McKenna

Consultant

Jim McKenna has over 15 years in medical research experience with a focus on neuroscience and the genetics of rare diseases.  He recently received his MBA from Emory University with a focus on strategy and marketing.  He worked in technical sales at a start-up Next Generation Sequencing company with an emphasis on growing sales and marketing to the academic community.  He is excited about the future of biopharma and passionate about leveraging new biotechnology in the treatment of rare diseases.

Jasmine Panesar

Consultant

Jasmine Panesar

Consultant

Jasmine has a background in medical biotechnology which she has successfully leveraged in clinical oncology research and big-pharma regulatory affairs strategy. She recently graduated from New York University with her second master’s in biotechnology focusing on entrepreneurship and data analytics. She is passionate about using creative solutions to bridge the gap between laboratory and real-world market for disease therapeutics. She deeply values ACS’s aim to reshape the future of rare disease.

Lily Nygren

Analyst

Lily Nygren

Analyst

Lily Nygren brings her interest in emerging biotechnologies, and their implementation into society, to the ACS team with passion and enthusiasm. She has in-depth experience researching Rotavirus and ways to inhibit its enterotoxin with altered amnio acid sites. Beyond the lab bench, her work in graduate school focused on genetic testing, its ethical considerations, and public health policy in today’s ever-changing health landscape. Lily holds a Bachelor’s in Biology from Bates College and a Master’s in Public Health and Bioethics from the John’s Hopkins Bloomberg School of Public Health. Lily is excited to propel ACS and its clients to far reaches in the field of rare disease biopharma.

Stephen Morreale

Analyst

Stephen Morreale

Analyst

Stephen Morreale has a strong background in synthetic biology and cellular programming and is passionate about pushing the limits of what is traditionally possible. Having previous experience working in start-ups, Stephen understands the importance of a creative approach to complex problems. A general curiosity in the "how" and "why" helps keep project theories in line with project goals.

Cameron Coyan

Analyst - Data Specialist

Cameron Coyan

Analyst - Data Specialist

Cameron Coyan is a multimedia specialist with 10+ years experience in all things digital. Specializing in data analytics and reporting, Cameron also excels at SEO, graphic design, and web development. Some of his accomplishments include established the standard for photographing medical products for Cardinal Health's B2B site, creating digital marketing campaigns for dental offices with +300% ROI, and helping to build brands/style guides for multiple clients. With an Electronic Media BA from the University of Cincinnati and certified in all things Google, he is passionate about making the web a more functional place and tracking marketing material to make sure they're preforming as intended.

Daniel Yaqub

Analyst

Daniel Yaqub

Analyst

Daniel brings multiple years of expertise in the biological field ranging from medical affairs and launch excellence to laboratory and field research, along with a fresh perspective and drive to improve the lives of those around us. ​

Prior to joining Ambit RD, Daniel was an Associate Consultant working with AstraZeneca in their Global Medical Affairs team, launching a novel therapy in multiple indications. Before his time with AZ, Daniel was a Researcher at George Washington University working to understand the genetics behind Hypertension. Daniel’s prior roles have given him extensive experience working cross-functionally, bridging the bench and patient, and balancing multiple stakeholders. ​

Daniel was raised in the Washington, DC Area and holds a Bachelors of Science degree in Biology from James Madison University. He currently resides in Arlington, Virginia.

Connor Starkey

Analyst

Connor Starkey

Analyst

Connor brings his analytical mindset and research driven perspective to the Ambit RD team where he is excited to help clients realize their full potential. Connor’s background conducting meta-analyses and literature reviews has poised him to be able to complete the data-heavy projects which are so common in the emerging biotech landscape. ​

Prior to joining Ambit, Connor completed his undergraduate degree in Neuroscience from Boston College. At BC, Connor gained invaluable research experience in a plethora of labs. Most notably, he completed his Senior Honors Thesis in Dr. Preston Thakral’s Human Neuroscience Lab alongside world-renowned memory researcher, Dr, Daniel Schacter. At Ambit, Connor has been able to apply this research background to multiple pipeline and valuation analyses. ​

Connor was raised in the Washington DC area before attending Boston College for his undergraduate degree. He currently resides in New York, NY.

Connect with ACS on LinkedIn

Ambit and ACS have merged! Learn how we are accelerating outcomes for patients and clients as a combined company.

Read More Here